Importance of concomitant topical therapy in moderate-to-severe atopic dermatitis treated with cyclosporine

Dermatologic Therapy
Jeong Eun KimYoung Suck Ro

Abstract

Cyclosporine (CS) is widely used in patients with refractory atopic dermatitis (AD). During CS treatment, many patients have a tendency to decrease their adherence to topical agents as their disease improves. Our aim was to compare the efficacy and relapse rate of CS treatment combined with topical therapy and CS monotherapy. This prospective, randomized, 6 month study involved 60 patients with moderate-to-severe AD who were randomly assigned to two groups, one receiving CS and topical agents and the other, CS only. Clinical outcomes were based on investigators' global assessment (IGA) scores, eczema areas and severity index scores, and trans-epidermal water loss. If a patient achieved treatment success (IGA score ≤2) during the study period, CS was stopped. Relapse rate and time to relapse were evaluated during the 3 months after discontinuation of CS. The treatment success rate was significantly higher in the combination group (p = 0.028). The combination group had a shorter median time to response (p = 0.040), a lower cumulative dose (p = 0.041), and a longer time to relapse (p < 0.01) than the monotherapy group. Although CS monotherapy is effective against AD, topical agents should be used concomitantly.

References

Jan 1, 1995·The British Journal of Dermatology·H GranlundS Reitamo
Jan 12, 1999·Journal of the European Academy of Dermatology and Venereology : JEADV·N Atakan, C Erdem
Jan 29, 2000·The British Journal of Dermatology·J I HarperJ Berth-Jones
Jul 15, 2000·Dermatology : International Journal for Clinical and Investigative Dermatology·P C van de KerkhofM V Kuipers
Apr 25, 2006·Journal of the American Academy of Dermatology·Jennifer Krejci-ManwaringSteven R Feldman
Apr 24, 2007·Journal of the European Academy of Dermatology and Venereology : JEADV·J SchmittM Meurer
May 1, 2008·Allergy·A WollenbergUNKNOWN European Tacrolimus Ointment Study Group
Nov 26, 2010·Journal of the American Academy of Dermatology·Karrie T AmorAlan Menter
Nov 26, 2010·Journal of the American Academy of Dermatology·Caitriona RyanAlan Menter
May 25, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·D Chrostowska-PlakJ C Szepietowski
Aug 7, 2012·Expert Opinion on Drug Delivery·Xi TanRajesh Balkrishnan
Sep 8, 2012·Dermatology Research and Practice·Y Valdman-GrinshpounA Zvulunov

❮ Previous
Next ❯

Citations

Sep 15, 2020·The Cochrane Database of Systematic Reviews·Ratree SawangjitNathorn Chaiyakunapruk
Dec 28, 2016·Dermatology and Therapy·Matteo MegnaNicola Balato
Oct 11, 2019·The Journal of Dermatology·Norito KatohKiwako Yamamoto-Hanada
Oct 20, 2020·Allergy·Doreen SiegelsUNKNOWN European Academy of Allergy, Clinical Immunology Atopic Dermatitis Guideline group
Nov 19, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·A WollenbergUNKNOWN European Task Force on Atopic Dermatitis/EADV Eczema Task Force
Mar 21, 2021·The Journal of Dermatology·Satoshi TakeuchiMasutaka Furue
Aug 3, 2021·Clinical Reviews in Allergy & Immunology·Huaguo LiZhirong Yao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.